Hypertension, antihypertensive medication use, and breast cancer risk in the California Teachers Study cohort by Largent, Joan A. et al.
ORIGINAL PAPER
Hypertension, antihypertensive medication use, and breast cancer
risk in the California Teachers Study cohort
Joan A. Largent • Leslie Bernstein • Pamela L. Horn-Ross • Sarah F. Marshall •
Susan Neuhausen • Peggy Reynolds • Giske Ursin • Jason A. Zell •
Argyrios Ziogas • Hoda Anton-Culver
Received: 14 October 2009/Accepted: 18 May 2010/Published online: 6 June 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Background We investigated the association between
hypertension, antihypertensive (AH) medication use, and
breast cancer in a large prospective study, the California
Teachers Study (CTS).
Methods Information on history of hypertension and
lifetime regular use of AH medications was collected from
114,549 women in 1995–1996. Among them, 4,151 inva-
sive breast cancers were diagnosed between 1995 and
2006. Additional information on AH use was collected
from 73,742 women in 2000–2001, and 1,714 of these
women were subsequently diagnosed with breast cancer.
Cox proportional hazards regression was used to estimate
relative risks (RR) and 95% conﬁdence intervals (CI) for
breast cancer.
Results Use of AH medication for C5 years, when
compared with no use, was associated with a modest
increased risk of invasive breast cancer (RR = 1.18,
95%CI 1.02–1.36). This increased risk appeared to be
conﬁned to estrogen receptor (ER)-positive tumors
(RR = 1.21, 95%CI 1.03–1.43) and pre-/peri-menopausal
women (RR = 1.58, 95%CI 1.11–2.25).
Conclusions Increased risk of invasive breast cancer was
observed for long-term (C5 years) AH use, and this
appeared to be conﬁned to ER ? breast cancer and
younger women.
Keywords Hypertension  Breast cancer 
Antihypertensive medication
Introduction
Breast cancer remains an important public health concern
as it represents the most common cancer diagnosis and
second leading cause of cancer-related death among
women in the United States [1, 2]. Obesity and obesity-
related conditions including hypertension, a highly pre-
valent condition among adult women, may be contributing
to the burden of post-menopausal breast cancer. A report
from the National Health and Nutrition Examination Sur-
vey (NHANES III) found that 22% of all U.S. females
18 years and older were hypertensive or taking AH medi-
cations in 1988–1991 [3].
Hypertension and AH medications have been consis-
tently associated with other malignancies, including renal
[4] and endometrial cancers [5], and with benign conditions
including uterine ﬁbroids [6]. However, results of studies
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tension, and AH medications have been inconsistent [7–9].
It has been suggested that the previously observed associ-
ations may be explained by uncontrolled confounding from
shared risk factors, such as increased obesity, a fat-rich
diet, or physical inactivity, alcohol use, and the absence of
lactation [10]. However, as both conditions may share
common pathophysiologic pathways involved in hormone
synthesis and metabolism [11, 12] and growth factor sig-
naling [13], it is possible that a biologic association exists.
Because hypertension is a highly prevalent condition
and AH medications are among the most commonly pre-
scribed drugs in the United States, the importance of
examining occurrence of any serious side effects including
inﬂuences on the risk of breast cancer has been suggested
[14]. Therefore, we sought to elucidate the relationship
between hypertension, AH medication use, and breast
cancer risk in a large prospective cohort of women, the
California Teachers Study (CTS).
Methods
Study population and data collection
The CTS is a prospective cohort study of 133,479 Cali-
fornia female teachers and school administrators who
completed a baseline survey in 1995–1996. A detailed
description of the study design and methods has been
published previously [15]. From among 118,262 partici-
pants who were residents of California at baseline and had
no prior history of breast cancer, we excluded members
who were over 85 years of age at baseline (n = 1,579) or
who had unknown history of hypertension or AH medica-
tion use (n = 2,134). The resulting cohort for the analysis
of data items collected at baseline consisted of 114,549
women. Women in this subcohort have been followed for
breast cancer incidence as well as other health outcomes
from the completion of the baseline survey through
December 31, 2006, their dates of death or the date of a
move out of California for more than four months,
whichever came ﬁrst. Incidence of invasive breast cancer
was ascertained through linkage with the statewide popu-
lation-based California Cancer Registry (CCR). During
follow-up, 4,151 women were diagnosed with invasive
breast cancer. National Cancer Institute designated Sur-
veillance, Epidemiology, and End Results (SEER) regis-
tries, including the CCR, routinely collect estrogen
receptor (ER) as recorded in the medical records following
a breast cancer diagnosis. ER status was available for 3,572
(86.0%) of the cases.
The baseline self-administered questionnaire asked
cohort members to indicate whether they had a history of
high blood pressure and whether they had taken the follow-
ing medications regularly (deﬁned as at least once a week):
‘‘Reserpine (Raudixin, Ser-Ap-Es, Hydropres, Rauwolﬁa,
Metatensin);’’ ‘‘Water pills for high blood pressure (Diuril,
Hydrodiuril, Dyazide, etc.);’’ or ‘‘Other high blood pressure
medications,’’ and if taken, to indicate duration of use (did
not take regularly, or took for less than 1 year, 2 years,
3–4 years, 5–9 years, 10? years), and if took regularly, the
frequency of use (1–3 days per week, 4–6 days per week,
every day). Duration variables includedin the analyses were
categorized as follows: Never regular use, less than or equal
to one year, 2–4 years, 5–9 years, or 10? years. An overall
variable ‘‘treated hypertension’’ was created which included
women with self-reported history of hypertension and also
use of at least one AH medication.
Statistical analysis
Risk factors included in the analyses as potential con-
founders were based on the data collected as part of the
self-administered baseline questionnaire. These included
family history of breast cancer (at least one affected ﬁrst-
degree relative, no affected ﬁrst-degree relatives, or
unknown/adopted); race/ethnicity (White; African-Ameri-
can; Hispanic; Asian/Paciﬁc Islander; or other/mixed/not
speciﬁed); body mass index (\20 kg/m
2;2 0t o\25 kg/m
2;
25 to \29 kg/m
2;3 0t o\35 kg/m
2; C35 kg/m
2;o r
unknown); smoking (never smoker; former smoker; current
smoker; or unknown); alcohol use in the year prior to
baseline, measured in average grams per day (no use; less
than 20 grams per day; 20 grams per day or more; or
unknown); physical activity, deﬁned as average lifetime
(from high school through current age or aged 54 if 55 or
older at baseline) moderate or strenuous activity per week,
(\2h ;2t o \4h ;4t o \6 h; 6 or more hours; or unknown);
a summary parity variable (ﬁrst full-term pregnancy
(FFTP) before age 25; FFTP age 25–29; nulliparous before
age 30; or unknown); breastfeeding history (never or less
than 12 months; at least 12 months; or unknown); hyster-
ectomy (never; ever; or unknown); menopausal status and
hormone therapy use (premenopausal; peri-menopausal;
post-menopausal and never used hormone therapy; post-
menopausal and ever used hormone therapy; or unknown
menopausal status or HT use); diabetes history (ever; or
never); and percent calories from fat, excluding alcohol
(quartiles). A variable for adherence to screening guide-
lines was created and deﬁned by age: for women age C40
at baseline having a mammogram within 1 year of base-
line; for women age\40 at baseline having a breast exam
by health care provider within 2 years or a mammogram
within 1 year of baseline (no; yes; or unknown). This
screening adherence variable was tested in the models, and
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was subsequently dropped.
More detailed information on AH medication use was
ascertained in a follow-up self-administered questionnaire
mailed tocohortmembersin2000–2001. This questionnaire
queried daily use of the following AH medications for at
least two months in the two years preceding the survey:
‘‘Thiazide diuretic (for example: Diuril, Hydrodiuril,
Dyazide);’’ ‘‘Lasix;’’ ‘‘Calcium blocker (for example:
Calan, Procardia, Cardizem);’’ ‘‘ACE inhibitors (for exam-
ple: Capoten, Vasotec, Zestril);’’ and ‘‘Other high blood
pressure medication.’’ This questionnaire was completed by
89,058 cohort members. Exclusions for this analysis inclu-
ded women who had moved out of California (n = 8,608),
who were diagnosed with breast cancer prior to completion
of this survey (n = 5,476), whose history of breast cancer
was unknown (n = 54), or who did not complete the AH
medication portion of the survey (n = 1,178). This analysis
was conducted independently of hypertension or AH med-
ication use reportedat baseline. These exclusionsresultedin
73,742 women eligible for analyses using the 2000–2001
questionnaire data. For these analyses, follow-up was initi-
ated on the date the questionnaire was completed and
women were followed until the ﬁrst of the following: inci-
dent breast cancer, death, a move out of California, or
December 31, 2006. In this period, 1,714 invasive breast
cancers were diagnosed.
Multivariable Cox proportional hazards regression
methods were used to estimate the relative hazard (referred
to herein as the relative risk, RR) for developing breast
cancer during the follow-up period; 95% conﬁdence
intervals (CI) were constructed around the point estimates
for the RRs [16] associated with history of hypertension
and AH medication use, using ages at start and end of
follow-up (in days) to deﬁne time on study. Models
included the covariates listed above and were stratiﬁed by
age at baseline (in single years of age).
All analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA).
Results
The distributions of selected baseline characteristics and
the age-adjusted differences of these factors by hyperten-
sion status are described in Table 1. The mean age at
baseline was 52.8, and the majority of women (86.4%)
were of non-Hispanic White race/ethnicity. A history of
high blood pressure was reported by 16.8% of the women.
The most common category of AH medication use reported
on the baseline questionnaire among all women was ‘‘other
high blood pressure medication’’ (13.0% of all women,
68.4% of hypertensives), followed by diuretics (10.0% of
all women, 45.3% of hypertensives) and reserpine (0.4% of
all women, 2.2% of hypertensives). Women with a history
of hypertension were signiﬁcantly older and more likely to
be non-White, to have a higher body mass index (BMI), to
have a history of diabetes, to be nulliparous at age of 30, to
be adherent to breast screening guidelines, to have had a
hysterectomy, and to consume a higher percent of calories
from fat than women without a history of hypertension.
Furthermore, hypertensive women were less likely to have
breastfed for 12 months or more or to have engaged in
moderate or strenuous physical activity over their lifetimes.
Table 2 presents associations between hypertension, AH
medication use, and breast cancer for both age-adjusted and
multivariable-adjusted models for the full cohort, with
analyses also presented by ER status. A history of treated
hypertension, when compared to either women without
hypertension or without AH medication use was not sig-
niﬁcantly associated with invasive breast cancer overall or
by ER subtype. Long-term use of any AH medication was
associated with increased risk of invasive breast cancer
overall (RR = 1.18, 95% CI 1.02–1.36; RR = 1.18, 95%
CI 1.04–1.34) for 5 and 10? years of use, respectively).
This association appeared to be conﬁned to ER-positive
breast cancer (RR = 1.21, 95% CI 1.03–1.43; RR = 1.26,
95% CI 1.10–1.45, for 5 and 10? years of use, respec-
tively). Ten or more years of diuretic use was also asso-
ciated with breast cancer overall and ER-positive subtype
(RR = 1.16, 95% CI 1.01–1.33; RR = 1.21, 95% CI 1.03–
1.42, respectively). Only 500 women reported regular use
of reserpine, which was not associated with breast cancer
risk (RR = 0.75, 95% CI 0.48–1.16).
Stratiﬁed analyses by categories of BMI (\25 kg/m
2;2 5
to \30 kg/m
2; and C30 kg/m
2) and menopausal status
(pre-/peri-menopausal; and post-menopausal) were per-
formed to evaluate whether risk of invasive breast cancer
associated with treated hypertension, diuretic, and other
AH medication use was modiﬁed by BMI or menopausal
status (Table 3). A history of hypertension treated with any
AH medication was not signiﬁcantly associated with
invasive breast cancer among any of the BMI categories
women (RR = 1.12, 95% CI 0.98–1.27; RR = 0.95, 95%
CI 0.81–1.11; RR = 1.09, 95% CI 0.90–1.32, for BMI
\25, 25 to \30, and C30 kg/m
2, respectively). Five or
more years of diuretic use was signiﬁcantly associated with
risk of breast cancer only among women in the highest
BMI category (RR = 1.12, 95% CI 0.93–1.37; RR = 1.05,
95% CI 0.85–1.30; RR = 1.31, 95% CI 1.03–1.66, for BMI
\25, 25 to\30, and C30 kg/m
2, respectively), and at least
5 years of use of ‘‘other’’ AH medications was associated
with invasive breast cancer risk among women in the
leanest and heaviest strata of BMI (RR = 1.20, 95% CI
1.01–1.42; RR = 1.00, 95% CI 0.82–1.22; RR = 1.35,
1.08–1.69, for BMI \25, 25 to \30, and C30 kg/m
2,
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123Table 1 Selected baseline characteristics and associations with a history of hypertension of 114,549 women in the California Teachers Study
Characteristic All women Women without hypertension Women with hypertension Age-adjusted
p-value
a
Mean
(SD)
n % Mean
(SD)
n % Mean
(SD)
n %
Age [years] 52.8 (13.9) 50.9 (13.4) 62.2 (12.1) \0.0001
Race/ethnicity \0.0001
White 98,997 86.4 82,480 86.6 16,517 85.6
Non-White
(includes unknown)
15,552 13.6 12,767 13.4 2,785 14.4
Family history of
breast cancer
0.01
None 97,393 85.0 81,312 85.4 16,081 83.3
At least one affected ﬁrst degree
Relative 13,484 11.8 11,024 11.6 2,460 12.7
Unknown 3,672 3.2 2,911 3.0 761 3.9
Body mass index (kg/m
2) \0.0001
\20 12,164 10.6 11,170 11.7 994 5.2
20 to\25 55,121 48.1 48,602 51.0 6,519 33.8
25 to\30 27,393 23.9 21,660 22.7 5,733 29.7
30 to\35 10,046 8.8 7,101 7.5 2,945 15.3
C35 5,589 4.9 3,558 3.7 2,031 10.5
Unknown 4,236 3.7 3,156 3.3 1,080 5.6
Hypertension
Never 95,247 83.1 95,247 100.0 0 0.0
Ever 19,302 16.8 0 0.0 19,302 100.0
Regular diuretic use
No 103,123 90.0 92,568 97.2 10,555 54.7
Yes 11,426 10.0 2,679 2.8 8,747 45.3
Regular reserpine use
No 114,049 99.6 95,178 99.9 18,871 97.8
Yes 500 0.4 69 0.1 431 2.2
Regular other antihypertensive
medication use
No 99,685 87.0 93,589 98.3 6,096 31.6
Yes 14,864 13.0 1,658 1.7 13,206 68.4
Diabetes \0.0001
Never 111,367 97.2 93,607 98.3 17,760 92.0
Ever 3,182 2.8 1,640 1.7 1,542 8.0
Smoking history 0.10
Never 75,682 66.1 63,936 67.1 11,746 60.8
Former 32,374 28.3 25,981 27.3 6,393 33.1
Current 5,828 5.1 4,778 5.0 1,050 5.4
Unknown 665 0.6 552 0.6 113 0.6
Alcohol use, average per
day in prior year (g/day)
\0.0001
No use 36,463 31.8 29,541 31.0 6,922 35.9
\20 63,184 55.2 53,663 56.3 9,521 49.3
20? 8,986 7.8 7,143 7.5 1,843 9.6
Unknown 5,916 5.2 4,900 5.1 1,016 5.3
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Characteristic All women Women without hypertension Women with hypertension Age-adjusted
p-value
a
Mean
(SD)
n % Mean
(SD)
n % Mean
(SD)
n %
Moderate/Strenuous
physical activity
(average lifetime) (h/week)
\0.0001
\2 36,148 31.6 28,331 29.7 7,817 40.5
2t o\4 29,075 25.4 24,413 25.6 4,662 24.2
4t o\6 19,168 16.7 16,429 17.2 2,739 14.2
6? 29,492 25.8 25,577 26.8 3,915 20.3
Unknown 666 0.6 497 0.5 169 0.9
Age at ﬁrst full-term
pregnancy (FFTP)
\0.0001
FFTP age\25 29,695 25.9 23,380 24.6 6,315 32.7
FFTP age 25–29 33,465 29.2 27,810 29.2 5,655 29.3
No full-term pregnancies
prior to age 30
42,359 37.0 36,304 38.1 6,055 31.4
Unknown 9,030 7.9 7,753 8.1 1,277 6.6
Breastfeeding history \0.0001
Never or less than
12 months
83,774 73.1 68,504 71.9 15,270 79.1
12? months 28,133 24.6 24,675 25.9 3,458 17.9
Unknown 2,642 2.3 2,068 2.2 574 3.0
Hysterectomy \0.0001
No 85,953 75.0 74,482 78.2 11,471 59.4
Yes 26,179 22.8 18,770 19.7 7,409 38.4
Unknown 2,417 2.1 1,995 2.1 422 2.2
Menopausal status and
hormone therapy use
\0.0001
Premenopausal 46,927 41.0 44,179 46.4 2,748 14.2
Peri-menopausal 2,361 2.1 2,012 2.1 349 1.8
Post-menopausal,
never HT use
12,015 10.5 8,668 9.1 3,347 17.3
Post-menopausal,
any HT use
39,379 34.4 29,034 30.5 10,345 53.6
Unknown 13,867 12.1 11,354 11.9 2,513 13.0
Adherence to screening
guidelines
b
\0.0001
No 41,109 35.9 33,347 35.0 7,762 40.2
Yes 48,911 42.7 38,942 40.9 9,969 51.6
Unknown 24,529 21.4 22,958 24.1 1,571 8.1
Percent calories from fat,
excluding alcohol
(quartiles)
\0.0001
First 26,064 22.8 21,718 22.8 4,346 22.5
Second 26,077 22.8 22,088 23.2 3,989 20.7
Third 26,062 22.8 21,885 23.0 4,177 21.6
Fourth 26,106 22.8 21,290 22.4 4,816 25.0
Unknown 10,240 8.9 8,266 8.7 1,974 10.2
a P-value for association with hypertension calculated using logistic regression adjusting for age at baseline
b For women age C40, mammogram within 1 year of baseline; for women age \40, breast exam by health care provider within 2 years or
mammogram within 1 year of baseline
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123respectively) and among pre-/peri-menopausal women
(RR = 1.58, 95% CI 1.11–2.25), but not among post-
menopausal women (RR = 1.10, 95% CI 0.98–1.24).
We were able to explore the effects of speciﬁc AH
medications based on data collected during the 2000–2001
survey. Associations between reported AH medication use
in the two years preceding the 2000–2001 survey and
breast cancer risk are presented in Table 4. Use of AH
medications including thiazide or furosemide diuretics,
calcium channel blockers, ACE inhibitors, or other anti-
hypertensive medications was not signiﬁcantly associated
with invasive breast cancer risk.
Discussion
In this large prospective cohort study, long-term use of AH
medication was associated with increased risk of invasive
breast cancer, and this risk appeared to be conﬁned to ER-
positive tumors, and among pre-/peri-menopausal women
and those who were in the lowest or highest categories of
BMI.
While there is fairly consistent evidence linking hyper-
tension and antihypertensive medications to renal cancer
[7] and hypertension to endometrial cancer [5, 7, 8, 17],
prior published studies of a hypertension-breast cancer
Table 2 Relative risk estimates for association between hypertension, antihypertensive (AH) medication use, and invasive breast cancer overall
and for estrogen receptor (ER) subtypes in baseline respondents in the California Teachers Study
Variable Observed
person-years
b
Invasive breast cancer ER ? breast cancer ER - breast cancer
No. of
cases
b
Age-adjusted
RR (95% CI)
Multivariable-
adjusted RR
(95% CI)
a
No. of
cases
Multivariable-
adjusted RR
(95% CI)
No. of
cases
Multivariable-
adjusted RR
(95% CI)
Treated hypertension
Never 991,013 3,341 1.0 (ref) 1.0 (ref) 2,443 1.0 (ref) 453 1.0 (ref)
Ever 155,427 810 1.06 (0.98–1.14) 1.06 (0.98–1.16) 585 1.09 (0.99–1.20) 91 0.98 (0.78–1.25)
Minimum duration of any AH medication use
No regular use 954,624 31,79 1.0 (ref) 1.0 (ref) 2,312 1.0 (ref) 432 1.0 (ref)
B 1 year 44,076 171 0.90 (0.77–1.05) 0.90 (0.77–1.06) 120 0.87 (0.72–1.05) 23 0.92 (0.60–1.41)
2–4 years 55,797 256 0.99 (0.87–1.13) 1.00 (0.88–1.14) 184 0.99 (0.85–1.15) 25 0.78 (0.51–1.16)
5–9 years 37,072 212 1.18 (1.02–1.36) 1.18 (1.02–1.36) 159 1.21 (1.03–1.43) 27 1.19 (0.80–1.78)
10? years 50,588 305 1.17 (1.04–1.32) 1.18 (1.04–1.34) 237 1.26 (1.10–1.45) 31 1.00 (0.69–1.47)
Regular diuretic use
No 1,038,514 3,598 1.0 (ref) 1.0 (ref) 2,628 1.0 (ref) 477 1.0 (ref)
Yes 107,926 553 1.05 (0.96–1.16) 1.06 (0.96–1.16) 400 1.04 (0.93–1.16) 67 1.06 (0.81–1.38)
Duration of diuretic use
No regular use 1,038,514 3,598 1.0 (ref) 1.0 (ref) 2,628 1.0 (ref) 477 1.0 (ref)
B 1 year 21,734 86 0.90 (0.73–1.12) 0.91 (0.74–1.13) 59 0.85 (0.66–1.10) 13 1.08 (0.62–1.87)
2–4 years 26,642 120 0.97 (0.81–1.16) 0.97 (0.81–1.17) 84 0.92 (0.74–1.15) 11 0.72 (0.40–1.32)
5–9 years 19,767 109 1.11 (0.92–1.35) 1.11 (0.92–1.35) 76 1.05 (0.84–1.33) 16 1.34 (0.81–2.22)
10? years 37,804 227 1.16 (1.01–1.32) 1.16 (1.01–1.33) 175 1.21 (1.03–1.42) 25 1.11 (0.73–1.67)
Regular other AH medication use
No 1,005,301 3,424 1.0 (ref) 1.0 (ref) 2,501 1.0 (ref) 456 1.0 (ref)
Yes 141,139 727 1.07 (0.99–1.17) 1.08 (0.99–1.18) 527 1.07 (0.97–1.18) 88 1.06 (0.84–1.35)
Duration of other AH medication use
No regular use 1,005,301 3,424 1.0 (ref) 1.0 (ref) 2,501 1.0 (ref) 456 1.0 (ref)
B 1 year 25,032 96 0.89 (0.73–1.10) 0.89 (0.73–1.10) 66 0.84 (0.66–1.08) 13 0.94 (0.54–1.63)
2–4 years 38,929 183 1.02 (0.87–1.18) 1.02 (0.88–1.18) 129 0.99 (0.83–1.18) 19 0.84 (0.53–1.34)
5–9 years 30,015 168 1.16 (0.99–1.35) 1.16 (0.99–1.36) 127 1.19 (0.99–1.43) 19 1.06 (0.67–1.69)
10? years 42,998 253 1.14 (1.00–1.30) 1.15 (1.01–1.31) 188 1.17 (1.00–1.36) 31 1.20 (0.82–1.76)
RRs in bold have p-values\0.05, and RRs underlined have p-values\0.01
a Age-stratiﬁed analyses adjusted for categories of race, family history of breast cancer, age at ﬁrst full-term pregnancy and number of full-term
pregnancies combined variable, hormone therapy and menopausal status combined variable, lifetime physical activity, diabetes, body mass
index, smoking history, alcohol use, hysterectomy, breastfeeding, and quartiles of percent calories from fat
b Person-years and number of cases may not add up to total due to rounding or unknown values
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123association have been inconsistent [7, 8, 18–20]. Some
prior studies included only women aged 50 and older [18,
19], while others included younger women as well [8, 20].
In the present study, we found the AH medication-breast
cancer association was most pronounced in younger
women. However, a study by Soler et al. [8] stratiﬁed by
age found the risk to be conﬁned to post-menopausal
women, and two additional studies reported signiﬁcant
hypertension and breast cancer associations among women
above age 50 at enrollment [18, 19]. Furthermore, with a
fairly long list of potential or established shared risk fac-
tors, it is possible that differential or inadequate adjustment
for such factors may also account for some of the incon-
sistencies. For example, not all prior studies accounted for
alcohol use [18], lifetime physical activity [8, 18–20],
breastfeeding [8, 18, 19], hormone therapy use [8, 18, 19],
hysterectomy [8, 18–20], or diabetes [8, 18]. Also, because
the magnitude of any true association between hyperten-
sion, AH medications, and breast cancer is likely weak,
there may be issues of inadequate power for smaller
studies. Studies which have stratiﬁed by BMI have tended
to report stronger associations of hypertension with breast
cancer among women with higher BMI [8, 19]. Stratiﬁca-
tion by BMI in the present study indicated that at least
5 years of use of other AH medication was associated with
invasive breast cancer among women in both the lowest
(\25 kg/m
2) and highest (C30 kg/m
2) categories of BMI,
but not for women in the middle category of BMI (25 to
\30 kg/m
2), and at least 5 years of diuretic use was
associated with invasive breast cancer only among women
in the highest (C30 kg/m
2) category of BMI. Furthermore,
when analyses were stratiﬁed by both menopausal status
and BMI (results not shown), associations between treated
hypertension, AH medication use, and invasive breast
cancer risk were conﬁned to pre-/peri-menopausal women
in the highest category of BMI.
An important challenge for research investigating the
interrelationships between hypertension, AH medications,
and breast cancer risk is that of disentangling the inde-
pendent effects of the condition versus pharmacologic
treatments. In a prospective study of hypertensive women
which included measures of diastolic blood pressure (DBP)
at baseline, increasing DBP was associated with increased
risk of breast cancer among women who were not taking
AH drugs but was inversely associated with risk among
women taking AH drugs [21]. In the longitudinal Women’s
Health Initiative Study, increasing baseline DBP also was
reported to be associated with a borderline increased risk of
total breast cancer (invasive and in situ), but not invasive
breast cancer alone [22]. A limitation of the present study
is lack of information about whether hypertension was
controlled by either AH medications or lifestyle modiﬁ-
cations as well as a lack of information about speciﬁc types
of medications beyond broad classes in the baseline ques-
tionnaire. Furthermore, with the exception of the antihy-
pertensive medications queried on the 2000–2001 survey,
both hypertension and AH medication use were recorded
on the baseline survey, and any changes that may have
occurred during years of follow-up could have resulted in
some misclassiﬁcation of exposure status.
Table 3 Relative risk estimates for association between hypertension, antihypertensive (AH) medication use, and invasive breast cancer by
strata of body mass index (BMI) and menopausal status in baseline respondents in the California Teachers Study
Strata Breast
cancer
cases, No.
History of treated
hypertension, RR
a
(95% CI)
Diuretic use, RR
a (95% CI) Other antihypertensive
medication use, RR
a (95% CI)
No Yes No
regular use
\5 years of use 5? years of use No
regular use
\5 years of use 5? years of use
BMI
\25 2291 1.0 (ref) 1.12 (0.98–1.27) 1.0 (ref) 0.77 (0.59–1.00) 1.12 (0.93–1.37) 1.0 (ref) 1.01 (0.83–1.23) 1.20 (1.01–1.42)
25–29 1127 1.0 (ref) 0.95 (0.81–1.11) 1.0 (ref) 1.00 (0.78–1.28) 1.05 (0.85–1.30) 1.0 (ref) 0.92 (0.73–1.16) 1.00 (0.82–1.22)
30? 569 1.0 (ref) 1.09 (0.90–1.32) 1.0 (ref) 1.08 (0.80–1.45) 1.31 (1.03–1.66) 1.0 (ref) 0.89 (0.66–1.19) 1.35 (1.08–1.69)
Menopausal status
Pre/peri-
menopausal
1016 1.0 (ref) 1.08 (0.83–1.41) 1.0 (ref) 0.82 (0.53–1.25) 1.13 (0.70–1.81) 1.0 (ref) 0.90 (0.63–1.28) 1.58 (1.11–2.25)
Post-
menopausal
2760 1.0 (ref) 1.05 (0.96–1.15) 1.0 (ref) 0.94 (0.80–1.11) 1.13 (1.00–1.28) 1.0 (ref) 0.96 (0.83–1.10) 1.10 (0.98–1.24)
a Age-stratiﬁed analyses adjusted for categories of race, family history of breast cancer, age at ﬁrst full-term pregnancy and number of full-term pregnancies
combined variable, lifetime physical activity, diabetes, smoking history, alcohol use, breastfeeding, and quartiles of percent calories from fat: analyses
stratiﬁed by BMI were further adjusted for hysterectomy, menopausal status, and hormone therapy use combined variable, and analyses stratiﬁed by
menopausal status were further adjusted for BMI
RRs in bold have p-values\0.05
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123AH medications have been associated with risk of vari-
ous malignancies. A pooled analysis of AH medication use
and risk of malignancies revealed a signiﬁcant association
between rauwolﬁa derivatives, including reserpine, and
breast cancer yielding a signiﬁcant 25% increase in breast
cancer risk [23]. This pooled analysis also supported an
association between diuretics and increased risk of renal
cell carcinoma while other AH drugs including ACE
inhibitors and calcium antagonists were not found to be
associated with cancer risk. In a case–control study among
women aged 65–79, Li and colleagues [24] reported that
thiazide diuretics (OR = 1.4, 95% CI 1.1–1.8), potassium-
sparing diuretics (OR = 1.6, 95% CI 1.2–2.1), and imme-
diate release calcium channel blockers (OR = 1.5, 95% CI
1.0–2.1) were associated with modest increased risk of
invasive breast cancer, however, no trend of increasing risk
with increasing duration of use was observed. It has been
suggested that insulin resistance among thiazide diuretic
users and increased insulin levels associated with use of
potassium-sparing diuretics are potential mechanisms
[24, 25] which could explain an association between
diuretic use and breast cancer. One additional [19] study
among women aged 50–75, but not other previous studies
[25–27], investigating the risk of breast cancer associated
with diuretic use, have reported a signiﬁcant association. It
is not clear in some of the prior studies whether in situ breast
cancers were included as outcomes [26, 27]. In the present
study, an association between thiazide diuretic use and
invasive breast cancer risk was not observed.
The observation in the present study of increased breast
cancer risk with long-term use of AH medication raises a
question as to whether it is the condition of hypertension
itself or exposure to medications which may inﬂuence
breast cancer risk. It is likely that long-term use of AH
medication is a surrogate marker for longer duration of a
hypertensive condition. However, certain AH medications
may have been taken for other conditions, including car-
diac arrhythmia (beta blockers, calcium channel blockers),
coronary artery disease with or without history of myo-
cardial infarction (beta blockers), congestive heart failure
Table 4 Relative risk estimates for association between classes of antihypertensive medication use and invasive breast cancer among follow-up
respondents in California Teachers Study
Variable n Observed
person-years
b
Invasive breast cancer
cases, no. (1,714 total)
Multivariable adjusted
RR (95% CI)
a
Any antihypertensive medication
No regular use 56,710 361,865 1,206 1.0 (ref)
Regular use within 2 years 17,032 103,558 508 1.09 (0.98–1.22)
Thiazide diuretic
No regular use 68,409 432,781 1,540 1.0 (ref)
Regular use within 2 years 5,324 32,583 172 1.16 (0.99–1.37)
Unknown 9 59 2
Furosemide diuretic (Lasix)
No regular use 72,175 457,054 1,664 1.0 (ref)
Regular use within 2 years 1,562 8,350 50 1.22 (0.91–1.65)
(Unknown) 5 19 0
Calcium channel blocker
No regular use 70,862 448,175 1,630 1.0 (ref)
Regular use within 2 years 2,873 17,208 84 1.05 (0.84–1.31)
Unknown 7 40 0
ACE inhibitor
No regular use 69,698 440,762 1,592 1.0 (ref)
Regular use within 2 years 4,034 24,593 122 1.05 (0.86–1.27)
Unknown 10 68 0
Other antihypertensive medication
No regular use 63,242 401,638 1,410 1.0 (ref)
Regular use within 2 years 10,441 63,428 303 1.04 (0.91–1.18)
Unknown 59 357 1
a Age-stratiﬁed analyses adjusted for categories of race, family history of breast cancer, age at ﬁrst full-term pregnancy and number of full-term
pregnancies combined variable, hormone therapy and menopausal status combined variable, lifetime physical activity, diabetes, body mass
index, smoking history, alcohol use, hysterectomy, breastfeeding, and quartiles of percent calories from fat
b Totals may not add up due to rounding
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123(ACE inhibitors, furosemide diuretics), diabetic nephrop-
athy (ACE inhibitors), or off-label usage such as diuretics
for weight loss. One hypothesis for why duration of
exposure to the condition of hypertension may be an
important factor in a hypertension-cancer association has
been reviewed by Hamet [13] who postulates that with
short-term exposure to hypertension, during the period in
which hypertension is developing, apoptosis is increased
which may be associated with reduced risk of cancer [28].
Long-term exposure, on the other hand, could be associated
with increased cancer risk as it is associated with cellular
senescence, telomere shortening [29], and inhibition of
apoptosis. Other potential biologic mechanisms contribut-
ing to an association between hypertension and cancer
include pathways shared in steroid hormone synthesis and
metabolism [12], angiogenesis [30], growth factor signal-
ing [31], and inﬂammation [22, 32].
Strengths of the current study include the prospective
design where hypertension and AH medication use were
assessed prior to follow-up for breast cancer incidence thus
largely eliminating the potential for recall bias. However,
because the primary exposures of interest, history of
hypertension, and AH medication use were primarily
assessed by self-report, the potential for misclassiﬁcation
exists. A recent NHANES report revealed that 87% of
hypertensive women in the United States. are aware of
their condition; further, less than 5% of women were
hypertensive, but had never been diagnosed by a health
care provider [33]. The sensitivity of self-reported antihy-
pertensive medication use among older women has been
reported to be 79–92% [34]. Any such misclassiﬁcation of
AH medication is, however, expected to be non-differential
with respect to breast cancer status, and thus our ﬁndings
should if anything be an underestimate of the true effects.
The ascertainment of incident breast cancer diagnoses
through linkage with the comprehensive population-based
CCR, rather than relying on self-reports, is another strength
of our study as case ascertainment is 99% complete in the
state of California [35].
The CTS cohort is also well characterized with respect
to covariates of interest which allowed for adjustment for
several potential confounding factors. While breast cancer
and hypertension appear to share many common risk fac-
tors, the age-adjusted and multivariate-adjusted risk esti-
mates were quite similar in this study, suggesting that the
covariates did not have a major inﬂuence on the association
between AH medications and breast cancer. However,
these effects were rather moderate, and so we cannot
exclude the possibility that residual confounding may
account for the observed associations.
In summary, it is difﬁcult to separate the independent
effects of the condition of hypertension itself (and varying
levels of severity and control) and treatment in the form of
AH medications on the risk of breast cancer. However,
given the high prevalence of both hypertension and AH
medication use, even small effects on breast cancer risk
could potentially have population-wide implications. Future
research into the biologic mechanisms may help disentangle
the etiological roles of hypertension itself versus the use of
speciﬁc antihypertensive medications in breast cancer risk.
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